A recent two-center, phase 1 feasibility and safety trial (ESCaPE-CMD, NCT03508609) using autologous CD34+ stem cells in INOCA patients with endothelial-independent CMD demonstrated a significant improvement in CFR, AF, CCS class and quality of life [21]. Here, CD34 is linked to atrial fibrillation.